PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Free Radic Biol Med. Author manuscript; available in PMC Mar 17, 2013.
Published in final edited form as:
PMCID: PMC3600120
NIHMSID: NIHMS449800
Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus
Rabea Asleh,a1 Farid M. Nakhoul,ab*1 Rachel Miller-Lotan,a Hoda Awad,a Dan Farbstein,a Nina S. Levy,a Nakhoul Nakhoul,b Theodore C. Iancu,c Irena Manov,c Michael Laue,d Maret G. Traber,e Katie M. Lebold,e and Andrew P. Levya
aDepartment of Anatomy and Cell Biology, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, 1 Efron St. Bat Galim, P.O.B. 9649, Haifa, Israel
bNephrology Department, Baruch-Padeh Poryia Medical Center, Bar Ilan University Faculty of Medicine, Lower Galilee, 15208, Poryia, Israel
cPediatric Research and Electron Microscopy Unit, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, 1 Efron St. Bat Galim, P.O.B. 9649, Haifa, Israel
dRobert Koch Institute, Nordufer 20, 13353, Berlin, Germany
eLinus Pauling Institute, Oregon State University, 307 Linus Pauling Science Center, Corvalis, OR, USA
Rabea Asleh: asl/at/yahoo.com; Farid M. Nakhoul: fnakhoul/at/poria.health.gov.il; Rachel Miller-Lotan: lotanr/at/tx.technion.ac.il; Hoda Awad: aw/at/yahoo.com; Dan Farbstein: dan.farbstein/at/gmail.com; Nina S. Levy: ninal/at/tx.technion.ac.il; Nakhoul Nakhoul: n/at/yahoo.com; Theodore C. Iancu: tiancu/at/tx.technion.ac.il; Irena Manov: irenamanov/at/gmail.com; Michael Laue: laueM/at/rki.de; Maret G. Traber: maret.traber/at/oregonstate.edu; Katie M. Lebold: leboldk/at/gmail.com; Andrew P. Levy: alevy/at/tx.technion.ac.il
*Corresponding author at: Poryia Medical Center, Bar Ilan University Faculty of Medicine, Poryia, Israel. fax: 972 4 6652587
1Both authors contributed equally to this manuscript.
The haptoglobin (Hp) genotype is a major determinant of progression of nephropathy in individuals with diabetes mellitus (DM). The major function of the Hp protein is to bind and modulate the fate of extracorpuscular hemoglobin and its iron cargo. We have previously demonstrated an interaction between the Hp genotype and the DM on the accumulation of iron in renal proximal tubule cells. The primary objective of this study was to determine the intracellular localization of this iron in the proximal tubule cell and to assess its potential toxicity. Transmission electron microscopy demonstrated a marked accumulation of electron-dense deposits in the lysosomes of proximal tubules cells in Hp 2-2 DM mice. Energy-dispersive X-ray spectroscopy and electron energy loss spectroscopy were used to perform elemental analysis of these deposits and demonstrated that these deposits were iron rich. These deposits were associated with lysosomal membrane lipid peroxidation and loss of lysosomal membrane integrity. Vitamin E administration to Hp 2-2 DM mice resulted in a significant decrease in both intralysosomal iron-induced oxidation and lysosomal destabilization. Iron-induced renal tubular injury may play a major role in the development of diabetic nephropathy and may be a target for slowing the progression of renal disease.
Keywords: Diabetes, Nephropathy, Lysosome, Iron-induced injury, Haptoglobin genotype, Oxidative stress
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) and accounts for approximately 40% of all patients who require renal replacement therapy [1]. Traditional risk factors and glycemic control are important but inadequate for predicting the incidence and severity of DN. The interindividual variability in the risk for developing DN and its clustering within families suggest a substantial genetic predisposition [2,3]. As reactive oxygen species, particularly those derived from iron, have been implicated in the progression of DN and other vascular complications of Diabetes, polymorphic genetic loci encoding variants in enzymes protecting against iron-induced oxidative stress serve as potential susceptibility determinants for the development of DN [47].
Haptoglobin (Hp) is an acute phase protein whose primary function is to neutralize the prooxidative activity and accelerate the clearance of extracorpuscular hemoglobin (Hb) [8]. In humans there exists a common functional allelic polymorphism at the Hp locus with two classes of alleles denoted 1 and 2. Seven independent longitudinal studies have demonstrated a direct relationship between the Hp genotype and the incident cardiovascular disease in DM with the Hp 2-2 genotype being associated with a 2- to 5-fold increased risk [9]. In the only published longitudinal study examining the relationship between incident DN and the Hp genotype Costacou and colleagues demonstrated in the EDC cohort that the Hp 2-2 genotype was an independent determinant of early renal functional decline and progression to ESRD in individuals with Type I DM [10]. We have recently confirmed in a second longitudinal cohort this association between incident early renal functional decline and progression to ESRD in Type I DM and the Hp genotype in the DCCT/EDIC cohort (A. Levy, unpublished observations).
We previously demonstrated in C57Bl/6 mice that in the setting of DM, replacement by homologous recombination of the wild-type Hp 1 allele with the Hp 2 allele converted this mouse strain from a nephropathy resistant to a nephropathy prone state. Hp 2-2 DM mice were shown to develop histological and functional (changes in creatinine clearance) changes representative of the early changes found in humans with DN [11]. Moreover, we demonstrated that these nephropathic changes occurring in Hp 2-2 DM mice could be prevented by vitamin E, suggesting that these changes were due to oxidative stress [11]. A striking histological feature in Hp 2-2 DM mice was a marked accumulation of iron (documented with Perl’s stain) exclusively in renal proximal tubule cells and this iron accumulation was associated with marked tubular hypertrophy [11]. A growing body of evidence suggests that the deterioration of renal function in DN correlates best with proximal tubular injury with tubular hypertrophy preceding and inducing hypertrophy and sclerosis of the glomeruli [12]. The primary objective of the present study was to determine the intracellular localization of iron in the renal proximal tubule cell of DM mice and to assess how it may result in proximal tubular cell damage.
Animal studies
All procedures were approved by the Animal Care Committee of the Technion (protocol number IL-112-11-11). All mice were of a C57B1/6 genetic background. The Hp 2 allele is present only in humans. All other species have only an Hp 1 allele, which is highly homologous with the human Hp 1 allele. Thus, wild-type mice carry the Hp 1 allele (referred herein as Hp 1-1 mice). The construction of the murine Hp 2 allele and the targeting of its insertion by homologous recombination to the murine Hp genetic locus have been previously described [13]. Mice were fed normal chow and in mice in which we sought to induce DM, intraperitoneal streptozotocin was administered (50 mg/kg for 5 subsequent days) at 10 weeks of age. Mice were sacrificed after a DM duration of 3 months (non-DM mice and DM mice were sacrificed at the same age). There were no differences in spot glucose levels between mice with the different Hp genotypes. For vitamin E studies, DM mice were treated with placebo or vitamin E (40 mg/kg/day administered in the drinking water [11])) beginning 1 month after the onset of DM; mice were sacrificed after 2 months of vitamin E or placebo treatment. After mice were sacrificed the kidneys were removed and washed in saline and either fixed in formalin for morphometric and immunohistological analysis [13], in glutaraldehyde for electron microscopy analysis, or placed in liquid nitrogen for biochemical and cell fractionation studies.
Transmission electron microscopy (TEM) [14,15]
Kidney tissue samples from Hp 1-1 and Hp 2-2 mice were immersed immediately on isolation into 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 2 h and then postfixed in osmium tetroxide for 1 h, dehydrated through a series of ethanol solutions, and embedded in epoxy. Semithin sections were used for orientation and selection. Ultrathin sections (60 nm) were cut with a diamond knife, mounted on 300-mesh copper grids, and either left unstained or stained with lead citrate for 2 min. Sections of four different blocks were viewed and photographed with a Jeol 100SX electron microscope operated at 80 kV. Electron micrographs at a magnification of 2000–80,000 were captured with an 11.1 megapixel CCD (SIA, Duluth, GA).
Energy dispersive X-ray spectroscopy (EDX) and electron energy loss spectroscopy (EELS)
EDX and EELS were performed with a Zeiss Libra 120 transmission electron microscope that was equipped with a Pheonix X-ray detector (EDAX) and an in-column Omega energy filter. EELS spectra were recorded with a digital camera at 120 kV and an energy resolution of 1.5 eV using the EFTEM software of Olympus soft imaging solutions. Sections were used without any on-section staining and were about 50 nm (EELS) or 80–120 nm (EDX) in thickness.
Lysosome purification
Lysosomes were purified from murine kidneys as previously described with some modifications [1618]. One kidney was removed to a chilled petri dish containing homogenization medium (HM: 0.25 M sucrose, 1 mM EDTA, 10 mM Hepes, pH 7.0) and finely minced. The tissue was suspended in 3 ml HM and transferred to a Potter-Elvehjem homogenizer and homogenized with 7 strokes. The homogenate was centrifuged twice for 10 min at 750 g at 4 °C, and the postnuclear supernatant (PNS) removed. The PNS was then incubated with 1.25 mM calcium chloride (resulting in swelling of the mitochondria, making them less dense and easier to separate from the lysosomal fraction during Percoll density centrifugation). The PNS was then centrifuged at 20,000g for 10 min at 4 °C. The resulting pellet was resuspended in 5.5 ml HM and mixed with 4.5 ml 90% Percoll in HM. This solution was then centrifuged for 30 min at 47,000g at 4 °C in Beckman ultracentrifuge tubes (No. 344059) after which the top 7 ml was removed with a pipette and the bottom 1.5 ml removed with a syringe connected to a needle. The bottom 1.5 ml was spun at 100,000g for 1 h in Beckman microultracentrifuge tubes (No. 343778) to pellet the Percoll. The turbid layer above the pellet was collected, suspended in HM, and kept at 4 °C until analysis. Protein concentrations were determined using the Bradford reagent. We monitored the purification of the lysosomes by following the specific activity of the lysosomal-specific markers acid phosphatase and cathepsin D (Sigma). We observed an approximately 50-fold enrichment during this purification procedure, similar to that previously described [16,18], in the specific activity of these lysosomal-specific markers compared to the whole cell homogenate. In order to assess contamination of the lysosomal preparation from other cell organelles we also assessed the activity of cytochrome c oxidase (mitochondria), cytochrome c reductase (endoplasmic reticulum), and catalase (peroxisome) (all assessed using marker-specific enzymatic assays from Sigma). We did not find detectable activity of these other organelle-specific markers, as previously described [16,18], in our lysosomal preparations used in these studies.
Assessment of lysosomal membrane integrity
Lysosomal membrane integrity was determined by measuring the activity of the lysosomal enzyme β-hexosaminidase using the fluorimetric substrate 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside [17]. Since intact lysosomal membranes prevent substrate access to the intralysosomal enzyme, no substrate turnover in a preparation of lysosomes indicates integrity of the lysosomal membrane.
Briefly, 50 μl of the lysosome preparation was incubated for 1 min at 37 °C with 250 μl of 100 mM citrate buffer, pH 4.5, containing 0.25 M sucrose, 20 mM sodium phosphate, pH 4.5, and 1.2 mM 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside with and without 0.2% Triton X-100. The reaction was terminated after 1 min by the addition of 1 ml of 0.5 M glycine/sodium carbonate buffer, pH 10. The liberated 4-methylumbelliferone was determined by measuring the fluorescence in a BMG GalaxyFlouroStar microplate reader with a 365/450 nm excitation/emission filter pair. The degree of lysosome injury was expressed as percentage fragility ([activity in the absence of detergent/activity in the presence of detergent] ×100).
Assessment of lysosomal membrane lipid peroxides
Lysosomal lipid peroxides were measured by adding to 100 μl of the lysosomal preparation, 1 ml of lipid peroxide reagent (0.2 M potassium hydrophosphate, 0.12 M potassium iodide, 0.15 M sodium azide, 2 g/L igepal, 0.1 g/L alkylbenzyldimethylammonium chloride, 10 μM ammonium molybdate). The mixture was vortexed and incubated for 30 min in the dark, and then the OD of the sample was measured at 365 nM. The concentrations of lipid peroxides were calculated as previously described [19].
Measurement of redox-active chelatable iron in kidney lysosomes
Assessment of redox-active chelatable iron has been described previously [20]. Briefly, dihydrorhodamine (DHR) was used as a sensitive fluorescent indicator of oxidative activity. To assess the amount of redox-active chelatable iron in lysosomal preparations, quadruplicates of 20 μl of purified lysosomes were transferred to clear-bottom 96-well plates and incubated with DHR (50 μM) in 180 μl iron-free Hepes-buffered saline containing 40 μM ascorbate in the presence and absence of 50 μM iron chelator (deferiprone). The kinetics of fluorescence increase were followed at 37 °C in a BMG GalaxyFlouroStar microplate reader with a 485/538 nm excitation/emission filter pair for 40 min. The slopes of the DHR fluorescence intensity over time were then determined. The difference in the rate of oxidation of DHR in the presence and absence of the chelator represents the specific component of iron that is catalytically redox active. The free redox-active iron concentrations (in μM) were then determined from calibration curves using Hepes-buffered saline with increasing concentrations of Fe:nitrilotriacetic acid (NTA).
Measurement of vitamin E
α- and γ-tocopherol concentrations, as well as total cholesterol concentrations (see below) were determined [21]. Tocopherols were analyzed by high performance liquid chromatography (HPLC) with electrochemical detection, using a modification of Podda et al. [21]. Briefly, samples were mixed with 2 ml 1% ascorbic acid in ethanol and 1 ml Milli-Q water (Millipore, Billerica, MA). Following addition of 300 μl saturated KOH, samples were saponified at 70 °C for 30 min. After cooling on ice and addition of 25 μl BHT, the samples were extracted with hexane, taken to dryness under nitrogen, resuspended in 70 μl 50:50 (v/v) ethanol–methanol, and then transferred to HPLC injection vials. The HPLC system consisted of a SCL-10 A VP Shimadzu (Kyoto, Japan) system controller, two LC-10AD VP Shimadzu pumps, a SIL-10AD VP Shimadzu autoinjector with sample cooler, a Brownlee Spheri-5 RP-18 precolumn (5 μm 30 ×4.6 mm), a Symmetry Shield RP18 (3.5 μm ×4.6 mm ×100 mm) column (Waters, Milford, MA), and a LC-4C amperometric electrochemical detector (Bioanalytical Systems, West Lafayette, IN). The mobile phase consisted of 0.1% (w/v) lithium perchlorate and 98:2 (v/v) methanol–water and was run isocratically at 0.6 ml/min/pump for 8 min. Cholesterol concentrations of the hexane extracts used for tocopherol analysis were determined by taking a known aliquot of the hexane to dryness under nitrogen. Cholesterol was then assayed using the Amplex Red Cholesterol Assay Kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. Specifically, cholesterol concentrations were determined fluorometrically using a SpectraMax Gemini XS microplate spectrofluorometer (Molecular Devices, Silicon Valley, CA) with an excitation wavelength of 545 nm and an emission wavelength of 590 nm. α-Tocophorol was normalized to cholesterol and expressed as nanomole α-tocophorol per miligram cholesterol.
Statistical analysis
All results are reported as means ± SEM. Comparison between groups was performed using ANOVA and the Tukey-Kramer honestly significant difference method for pairwise comparisons, with a P value of <0.05 considered significant. For determination of the percentage of tubule cell lysosomes which contained electron-dense deposits per mouse, all lysosomes from 30 fields per mouse (TEM, magnification 10,000 ×) were used. For determination of the average size of electron-dense deposits in the lysosome per mouse, in those lysosomes which had visible deposits, the average percentage of lysosomal area of 10 lysosomes per mouse was determined (also determined at 10,000 × magnification). In order to ascertain if there was a significant difference between Hp 1-1 and Hp 2-2 DM mice in the percentage of lysosomes which had electron-dense deposits or in the average size of these deposits, P values were determined comparing the average values calculated for each mouse.
Increased iron-rich deposits in lysosomes of proximal tubule cells in Hp 2-2 DM mice
We sought to assess the intracellular localization of iron within the proximal tubules using TEM. TEM demonstrated a marked accumulation of electron-dense deposits in the lysosomes of proximal tubule cells (Fig. 1A). EDX and EELS were used to perform elemental analysis of these deposits and demonstrated that these deposits were iron rich (Fig. 1B). Lysosomes containing these iron deposits were more frequent in the proximal tubule of Hp 2-2 (65±4% of all lysosomes) compared with Hp 1-1 DM mice (41±4% of all lysosomes, P<0.05) (Fig. 1A). The deposit sizes were approximately double within Hp 2-2 DM lysosomes as compared to those within lysosomes from Hp 1-1 DM mice (P<0.05) (Fig. 1A). Fig. 1C demonstrates that the electron-dense deposits were surrounded by a single membrane (not visible at lower magnifications as in Fig. 1A) and hence are located completely within the lysosome.
Fig. 1
Fig. 1
Increased iron-rich deposits in lysosomes of proximal tubule cells in Hp 2-2 DM mice. TEM and EDX were performed as described in methods. (A) Increased presence and size of electron-dense deposits in lysosomes of Hp 2-2 DM mice. TEM of proximal tubule (more ...)
Intralysosomal redox-active iron concentrations are markedly increased in Hp 2-2 DM mouse kidneys
In order to further characterize the biochemical properties and functional significance of these iron-rich lysosomal deposits, we isolated lysosomes from Hp 1-1 and Hp 2-2 DM mice monitoring the specific activity of lysosomal and other organelle-specific enzymes to assess the purity of the preparation. In order to determine if the increased iron-rich deposits in Hp 2-2 DM mice had the potential to produce reactive oxygen species, we assessed redox-active chelatable iron in lysosomes of Hp 1-1 and 2-2 DM mice. We found a 2-fold increase in the amount of redox-active iron in the lysosomes of Hp 2-2 DM mice (0.56±0.07 μM) as compared with those from Hp 1-1 DM mice (0.23±0.14 μM, n=6 in each group, P=0.036).
Lysosomal membrane lipid peroxides are increased in Hp 2-2 DM proximal tubule cell lysosomes
Having demonstrated that lysosomes from Hp 2-2 DM mice contain increased redox-active iron, we next sought to determine if this iron was associated with an increase in lysosomal membrane lipid peroxidation. Lysosomal lipid peroxides were significantly increased in Hp 2-2 DM mice (n=6 in each group, P<0.0001 for one-way ANOVA and P<0.001 for all pairwise comparisons between the Hp 2-2 DM and the other three groups) (Fig. 2).
Fig. 2
Fig. 2
Lysosomal lipid peroxides are significantly increased in the lysosomes of Hp 2-2 DM kidneys The amount of lipid peroxides is presented as the mean±SEM for each group. Lysosomal lipid peroxides were significantly increased (*) in Hp 2-2 DM mice (more ...)
Lysosomal membrane integrity is compromised in Hp 2-2 DM proximal tubule cell lysosomes
In order to determine if the increased lysosomal membrane peroxidation was associated with the loss of lysosomal membrane integrity, we measured the specific activity of an intralysosomal enzyme, β-hexosaminidase, in lysosomal preparations from Hp 1-1 and Hp 2-2 mice with and without DM. Membrane integrity was significantly decreased in the lysosomes purified from the kidneys of Hp 2-2 DM mice as compared to all other groups (n=6 in each group, P<0.003 by ANOVA comparing all 4 groups, and P<0.01 for pairwise comparisons between Hp 2-2 DM and the other three groups) (Fig. 3).
Fig. 3
Fig. 3
Lysosomal membrane integrity is reduced in proximal tubule lysosomes in Hp 2-2 DM mice. Lysosomal membrane integrity was assessed in lysosomal preparations purified from kidneys of Hp 1-1 and Hp 2-2 DM and non-DM mice using the β-hexosaminidase (more ...)
Proof of concept that the loss of lysosomal membrane integrity in Hp 2-2 DM proximal tubule cells is due to oxidative damage
We sought to evaluate the role of lipid peroxidation in the maintenance of lysosomal membrane integrity by showing that chronic administration of the lipid-soluble antioxidant, vitamin E, could decrease lysosomal membrane oxidation and maintain lysosomal membrane integrity. Vitamin E supplementation resulted in a significant 45% reduction in lysosomal redox-active iron in Hp 2-2 DM mice (n=6, P<0.04) with no significant effect on lysosomal redox-active iron in Hp 1-1 DM mice. Moreover, we found that vitamin E supplementation significantly decreased lysosomal lipid peroxides in Hp 2-2 DM kidneys as compared with lysosomal preparations of Hp 2-2 DM mice treated with placebo (75.7±8.7 nmol lipid peroxides/mg protein for Hp 2-2 DM with vitamin E vs 109.2+/−8.8 nmol lipid peroxides/mg protein for Hp 2-2 DM without vitamin E, n=6 in each group, P=0.03). There was no significant reduction in lysosomal lipid peroxides in Hp 1-1 DM mice treated with vitamin E (Fig. 4A). Moreover, there was a significant correlation between lysosome membrane α-tocophorol concentrations and the degree of lysosomal membrane oxidation in Hp 2-2 DM mice but not in Hp 1-1 DM mice (Fig. 5A; n=12 for both groups, correlation coefficient=0.79, P<0.003 for correlation of vitamin E and lysosomal lipid peroxides in Hp 2-2 DM and correlation coefficient=0.54, P=0.07 for correlation of vitamin E and lysosomal lipid peroxides in Hp 1-1 DM mice). Finally, we found a significant reduction in the loss of lysosomal membrane integrity in lysosomes purified from kidneys of Hp 2-2 DM mice treated with vitamin E as compared with those treated with placebo (24.1%±2.3 for vitamin E group vs 30.7%±1.7 for placebo group, n=6 per group, P=0.03). No significant differences in lysosomal membrane integrity were found after vitamin E administration to Hp 1-1 DM mice as compared to those treated with placebo (19.9%±2.7 for vitamin E group vs 22.1%±2.3 for placebo group, n=6, P=0.24) (Fig. 4B). There was a significant correlation in Hp 2-2 DM mice, but not in Hp 1-1 DM mice, between the concentration of vitamin E in the lysosomal membrane and the lysosomal membrane integrity (Fig. 5B; n=12 for both groups, correlation coefficient 0.72, P<0.008 for correlation of vitamin E and lysosomal integrity in Hp 2-2 DM and correlation coefficient=0.53, P=0.08 in Hp 1-1 DM mice).
Fig. 4
Fig. 4
Effect of vitamin E supplementation on lysosomal membrane lipid peroxides and membrane integrity. (A) Lysosomal membrane lipid peroxides were significantly reduced in Hp 2-2 DM mice which received vitamin E supplementation as compared to Hp 2-2 DM mice (more ...)
Fig. 5
Fig. 5
Lysosomal vitamin E concentration is correlated with lysosomal membrane lipid peroxidation and lysosomal membrane integrity. Vitamin E was measured in lysosomal preparations as described in the methods section and normalized to cholesterol. Filled symbols (more ...)
In this study we have demonstrated that increased lysosomal redox-active iron results in lysosomal membrane injury in renal cells of Hp 2-2 DM mice. These data therefore provide a novel pathophysiological mechanism explaining why the progression to end-stage renal disease is increased in DM individuals with the Hp 2-2 DM genotype. Moreover, the interaction between the vitamin E and the Hp genotype on lysosomal injury suggests that a pharmacogenomic paradigm of selective administration of vitamin E to Hp 2-2 DM individuals may offer considerable renal protection similar to that recently demonstrated for cardiovascular disease [22].
There exists prior evidence that proximal tubule cell lysosomal iron overload is a common pathogenic feature of early diabetic nephropathy [23]. Nankivell and colleagues demonstrated a dramatic increase in lysosomal iron deposition in biopsies from individuals with DN as compared to normal controls [23]. Moreover, the amount of proximal tubule cell iron deposition was highly correlated with the degree of loss of renal function in these individuals. While the Hp genotype of these individuals in this prior study was not reported this prior study demonstrates the relevance of the findings of the current study done in mice to DN in man.
Proximal tubule cell lysosomal iron accumulation has also been demonstrated in human biopsy specimens from individuals with early diabetic nephropathy, although the Hp-type relationship in these specimens was not investigated. As lysosomes were derived from whole kidneys, theoretically the compromise in lysosome membrane integrity demonstrated in this study may have occurred in any renal cell type. However, we assert that the changes described here in lysosomal structure and function are specific for proximal tubule cells. We have shown that the lysosomal injury is due to iron accumulating in the lysosome. The focus on proximal tubule cells is based on prior data [11,20] showing that Perl’s iron stain is present only in proximal tubule cells and not in the glomerulus and its constituent cells nor in other tubular or interstitial cells. It is axiomatic that in the absence of a Perl’s stain there is no possibility that cells other than the proximal tubular cells are iron overloaded in the Hp 2-2 DM mice. Furthermore, these other renal cell types do not have iron deposits by EM as we have shown here in proximal tubule cells.
The source of excess proximal tubule iron in Hp 2-2 DM is Hb [20]. In Hp 2-2 DM the normal clearance mechanism via the CD163 receptor [24] for the Hp–Hb complex is severely impaired with an approximate 5-fold increase in the half -life of the complex [22]. Consequently the steady-state levels of the complex are higher in Hp 2-2 DM [22]. Moreover, in DM the glomerular filtration barrier is perturbed, thereby allowing complexes such as Hp–Hb to cross the barrier. Proximal tubule cubulin and megalin have both been demonstrated to bind to Hb in the glomerular filtrate, mediating Hb uptake into proximal tubule cells, and may serve as an entry point into these cells for the Hp–Hb complex [25]; however other siderophores such as neutrophil gelatinase-associated lipocalin may also mediate this process [26]. The endocytosed Hp–Hb complex is then targeted to the lysosome where it is degraded [25]. As the half-life of Hp 2-2-Hb and Hp 1-1-Hb in the lysosome does not appear to be different[27], the differences observed in the steady-state amount of proximal tubule iron in mice with the Hp 1-1 or Hp 2-2 genotypes results from the greater flux of iron through the renal proximal tubule cell in Hp 2-2.
The form in which excess iron is found in lysosomes of Hp 2-2 DM mice appears to be as cross-linked iron-rich protein complexes such as ferritin, hemosiderin, and lipofuscin based on the characteristic features of these complexes on TEM [15]. This excess iron in Hp 2-2 DM renal proximal tubule lysosomes is redox active and may therefore result in cellular toxicity. The lysosome membrane appears to be better geared for oxidative insults than other cellular membranes, as it is enriched with antioxidants (vitamin E); the vitamin E content of the lysosome membrane is 40 times greater than that of the cytoplasmic membrane [28]. While the lysosome may be geared to deal with oxidants such as iron, the unique properties of the Hp 2-2–Hb complex in the setting of DM may overwhelm its antioxidative defenses [29,30]. The Hp 2-2–Hb complex may act as a Fenton reagent, and in the setting of DM, peroxide production may be sufficiently high to promote a large increase in hydroxyl radical formation via Fenton chemistry [31].
Lysosomal injury has recently been suggested as a new pathophysiological paradigm playing a major role in a wide range of chronic diseases ranging from atherosclerosis to neurodegenerative disease [32]. A loss of lysosomal membrane integrity would be expected to lead to the ability of degradative enzymes present in the lysosome to enter the cytosol and wreak havoc, leading to cell injury and death. We propose that any cell that endocytoses the Hp–Hb complex may develop lysosomal injury but with the exception of macrophages, no other cell type other than the proximal tubule cell has a mechanism to endocytose this complex. Consistent with this hypothesis, we have recently demonstrated that macrophages release cathepsin D (an intralysosomal enzyme) into the cytoplasm after taking up Hp 2-2–Hb complexes (unpublished observations) and this may explain the association of the Hp type with atherosclerotic plaque rupture in DM [33]. The loss of lysosomal integrity would also be expected to interfere with the maintenance of the acidic pH gradient present in the lysosome and therefore interfere with lysosome degradative functions conceivably leading to a defect in autophagy [32].
In conclusion, we have provided evidence for a novel mechanism whereby the Hp genotype may predispose to renal injury in the setting of DM. Elimination of excess proximal tubule iron, or its dangerous oxidative potential, possibly by a combination of iron chelating agents [34] and/or antioxidants [35] may thus prove helpful in the prevention of DN in DM individuals with the Hp 2-2 genotype.
Acknowledgments
This work was supported by a grant from the Israel Society Foundation (ISF) to F.M. Nakhoul and in part from Aboutboul Family in memory of Daniel Aboutboul and by grants from NIH (R01DK085226) and the ISF to A.P.L. This work was also generously supported by a grant from the Slava Smolakovski Fund to the Rambam-Atidim Academic Excellence Program. The electron-microscopic analyses were supported by the Dan David Foundation to T.C.I. and I.M. M.L. thanks Gerd Fulda for operating the microscope. A.P.L. is the author of a patent which is owned by his institution that claims that the Hp genotype is predictive of DM complications. He is also a consultant for Haptocure which has licensed this patent from his institution. R.A., F.N., R.M.L., H.A., D.F., N.S.L., N.N., T.C.I., I.M., M.L., M.G.T., and K.M.L. were involved in generating research data and reviewing the manuscript. R.A., F.N., and A.P.L. wrote the manuscript.
Abbreviations
DNDiabetic nephropathy
ESRDEnd-stage renal disease
HpHaptoglobin
DMDiabetes mellitus
EDCEpidemiology of diabetic complications
DCCT/EDICDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
TEMTransmission electron microscopy
EDXEnergy dispersive X-ray spectroscopy
EELSElectron energy loss spectroscopy
DHRDihydrorhodamine

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787. [PubMed]
2. Pezzolesi MG, Skupien J, Mychaleckyj JC, Warram JH, Krolewski AS. Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection. Semin Nephrol. 2010;30:126–140. [PMC free article] [PubMed]
3. Conway BR, Maxwell AP. Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron Clin Pract. 2009;112:c213–21. [PubMed]
4. Makuc J, Petrovic D. A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy. Cardiovasc Hematol Agents Med Chem. 2011 [PubMed]
5. Peterlin B, Globocnik Petrovic M, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. J Hum Genet. 2003;48:646–649. [PubMed]
6. Cilensek I, Mankoc S, Petrovic MG, Petrovic D. GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy. Dis Markers. 2012;32:93–99. [PMC free article] [PubMed]
7. Zorc M, Hruskovicová H, Petrovic MG, Milcic M, Peterlin B, Petrovic D. Haemochromatosis-causing mutations C282Y and H63D are not risk factors for coronary artery disease in Caucasians with type 2 diabetes. Fol Biol (Praha) 2004;50:69–70. [PubMed]
8. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–1600. [PubMed]
9. Farbstein D, Levy AP. The genetics of vascular complications in diabetes mellitus. Cardiol Clin. 2010;28:477–496. [PMC free article] [PubMed]
10. Costacou T, Ferrell RE, Ellis D, Orchard TJ. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes. 2009;58:2904–2909. [PMC free article] [PubMed]
11. Nakhoul FM, Miller-Lotan R, Awad H, Asleh R, Jad K, Nakhoul N, Asaf R, Abu-Saleh N, Levy AP. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. Am J Physiol Renal Physiol. 2009;296:F830–F808. [PubMed]
12. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177–186. [PubMed]
13. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2007;27:134–140. [PubMed]
14. Iancu TC, Perl DP, Sternlieb I, Lerner A, Leshinsky E, Kolodny EH, Hsu A, Good PF. The application of laser microprobe mass analysis to the study of biological material. Biometals. 1996;9:57–65. [PubMed]
15. Iancu TC. Ferritin and hemosiderin in pathological tissues. Electron Microsc Rev. 1992;5:209–229. [PubMed]
16. Graham JM. Isolation of lysosomes from tissues and cells by differential and density gradient centrifugation. Curr Protoc Cell Biol Chap3:Unit. 2001;3:6. [PubMed]
17. Schutt F, Bergmann M, Holz FG, Kopitz J. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol. 2002;240:983–988. [PubMed]
18. Harikumar P, Darshini T, Dutt A, Ninjoor V. A rapid procedure for the isolation of lysosomes from kidney cortex by Percoll density gradient centrifugation. J Biosci. 1989;14:269–277.
19. el-Saadani M, Esterbauer H, el-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627–630. [PubMed]
20. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96:435–441. [PubMed]
21. Podda M, Weber C, Traber MG, Packer L. Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols, and ubiquinones. J Lipid Res. 1996;37:893–901. [PubMed]
22. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes. 2008;57:2794–2800. [PMC free article] [PubMed]
23. Nankivell BJ, Tay YC, Boadle RA, Harris DC. Lysosomal iron accumulation in diabetic nephropathy. Ren Fail. 1994;16:367–381. [PubMed]
24. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201. [PubMed]
25. Gburek J, Verroust PJ, Willnow TE, Fyfe JC, Nowacki W, Jacobsen C, Moestrup SK, Christensen EI. Megalin and cubilin are endocytic receptors involved in renal clearance of hemoglobin. J Am Soc Nephrol. 2002;13:423–430. [PubMed]
26. McCullough PA, Williams FJ, Stivers DN, Cannon L, Dixon S, Alexander P, Runyan D, David S. Neutrophil gelatinase associated lipocalin: a novel marker of contrast nephropathy risk. Am J Nephrol. 35:509–514. (epub ahead of print) [PubMed]
27. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193–1200. [PubMed]
28. Rupar CA, Albo S, Whitehall JD. Rat liver lysosome membranes are enriched in alphatocopherol. Biochem Cell Biol. 1992;70:486–488. [PubMed]
29. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833–840. [PubMed]
30. Lin Y, Epstein DL, Liton PB. Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress. Invest Ophthalmol Vis Sci. 2010;51:6483–6495. [PMC free article] [PubMed]
31. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98:3693–3698. [PubMed]
32. Kurz T, Eaton JW, Brunk UT. Redox activity within the lysosomal compartment: implications for aging and apoptosis. Antioxid Redox Signal. 2010;13:511–523. [PubMed]
33. Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento PA, Winterstern A, Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol. 2008;52:1049–1051. [PubMed]
34. Persson HL, Yu Z, Tirosh O, Eaton JW, Brunk UT. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med. 2003;34:1295–1305. [PubMed]
35. Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, Levy NS, Miller-Lotan R, Asleh R, Levy AP. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010;11:675–684. [PMC free article] [PubMed]